首页 / 专利分类库 / 有机化学 / 无环或碳环化合物 / 含连接在同一个碳架上的氨基和羟基的化合物 / ·与同一个碳架的非环碳原子连接的羟基和氨基
序号 专利名 申请号 申请日 公开(公告)号 公开(公告)日 发明人
1 利用固载化的双辛可尼类生物配体进行不对称羟胺化和双羟化反应的方法 CN200310108401.0 2003-11-04 CN1524835A 2004-09-01 林国强; 刘汉泉; 杨细文; 徐明华
发明涉及一类利用合成的高分子固载化的双辛可尼类生物配体进行不对称羟胺化反应和双羟化反应的方法,反应产物的产率和对映选择性高,催化剂能反复使用,该方法尤其适用于合成紫杉醇(Taxol)及其C13边链的大规模生产。所用的高分子固载化的双辛可尼类生物碱配体具有如上结构式,其中PEG是聚乙二醇,R=H或OCH3。
2 基丁酸衍生物 CN98811901.3 1998-09-07 CN1282319A 2001-01-31 高桥宽治; 杉浦恒行
发明提供了通式(Ⅰ)所示的基丁酸衍生物及其盐(其中各符号如说明书中所定义)。这些衍生物能够抑制基质金属蛋白酶,因而可用于预防和/或治疗湿、骨关节炎、病理性吸收、骨质疏松症、牙周炎、间质性肾炎、动脉硬化、气肿、肝硬化、膜损伤、癌细胞的转移和渗入或其增生所致疾病、自身免疫病(如Crohn病、Sjogren病),白细胞经血管渗出或渗入所致疾病、血管再生、多发性硬化、主动脉瘤、子宫内膜异位等疾病。
3 用于递送活性剂的8-(2-羟基苯基)辛基二乙醇胺和其盐 CN200580019305.6 2005-04-18 CN1968919A 2007-05-23 D·克施内德纳
发明提供了8-(2-羟基苯基)辛基二乙醇胺和其盐、包含它们和一种或多种活性剂的组合物以及用它们施用活性剂的方法。本发明的递送剂非常适合用于与活性剂一起形成用于口服、结肠内、和其它施用途径施用于动物的非共价混合物。
4 神经酸苷酶抑制剂RO-64-0796的制备方法 CN00118139.4 2000-06-09 CN1191230C 2005-03-02 M·卡普弗; R·特鲁萨蒂
发明提供了一种下式(I)的1,2-二基化合物和其可药用加成盐的多步骤制备方法,其中,R1、R1′、R2和R2′如说明书中所定义,所述化合物由下式(II)的1,2-环化物制备,其中R1、R1′、R2和R2′如说明书中所定义。
5 在羟基溶剂中制备N-烷基多基胺及由此制备脂肪酸酰胺的方法 CN91109768.6 1991-09-27 CN1061958A 1992-06-17 J·沙伊贝尔; D·S·康纳尔; R·E·舒梅特; J·C·T·R·B·圣洛朗
在羟基溶剂如甲醇中,胺如甲胺与物料如还原性糖反应,制备N-烷基多羟基胺。相应地,葡萄糖与甲胺反应,并且将产生的加合物氢化,产生N-甲基葡糖胺。接着,N-烷基多羟基胺可与脂肪酯反应,得到可用作洗涤表面活性剂的多羟基脂肪酸酰胺。因此,洗涤表面活性剂可从非石油化学的产物母体,如糖和诸如玉米浆的糖原料以及衍生自各种脂和油的脂肪酸酯而得到。
6 在低温炼油厂和天然气加工中使结垢腐蚀溶剂降解最小化的方法 CN202080088753.6 2020-12-16 CN114787325A 2022-07-22 J·索里亚
一种清除的方法,所述方法包括(i)提供氧清除剂组合物;和(ii)将所述氧清除剂组合物加入到加工系统的性进料和/或烃进料中。
7 一种十六烷基甲基二羟乙基溴化铵的制备方法 CN201310351862.4 2013-08-13 CN103382157A 2013-11-06 李白千; 彭晓翊; 陈悦凯; 郑成; 毛桃嫣; 黄武欢; 陈瑞兰; 罗方然; 周虹谷
发明公开了一种十六烷基甲基二羟乙基溴化铵的制备方法。包括:称取N-甲基二乙醇胺和溴代十六烷置于配有机械搅拌器、回流冷凝管、温度计的三口烧瓶中,油浴锅加热反应;充分反应后,采用乙酸乙酯与无乙醇混合液对粗产物进行重结晶,抽滤得亮白色晶体,真空干燥后即得。本发明以N-甲基二乙醇胺与溴代十六烷为原料,采用无溶剂法合成了十六烷基甲基二羟乙基溴化铵季铵盐表面活性剂,制备过程不采用溶剂,从而减少了有机溶剂带来的污染与回收的成本。所制得的产品具有良好的增溶性能、泡沫性能及乳化性能。
8 利用固载化的双辛可尼类生物配体催化不对称羟胺化和双羟化反应的方法 CN200310108401.0 2003-11-04 CN1239441C 2006-02-01 林国强; 刘汉泉; 杨细文; 徐明华
发明涉及一类利用合成的高分子固载化的双辛可尼类生物配体催化不对称羟胺化反应和双羟化反应的方法,反应产物的产率和对映选择性高,催化剂能反复使用,该方法尤其适用于合成紫杉醇(Taxol)及其C13边链的大规模生产。所用的高分子固载化的双辛可尼类生物碱配体具有如右结构式:其中PEG是聚乙二醇,R=H或OCH3。
9 神经酸苷酶抑制剂RO-64-0796的制备方法 CN00118139.4 2000-06-09 CN1277957A 2000-12-27 M·卡普弗; R·特鲁萨蒂
发明提供了一种右式(Ⅰ)的1,2-二基化合物和其可药用加成盐的多步骤制备方法,其中,R1、R1′、R2和R2′如说明书中所定义,所述化合物由右式(Ⅱ)的1,2-环化物制备,其中R1、R1′、R2和R2′如说明书中所定义。
10 在胺和胺/溶剂中制备N-烷基多羟基胺和由该N-烷基多羟基胺制备脂肪酸酰胺的方法 CN91109859.3 1991-09-27 CN1061959A 1992-06-17 R·E·舒梅特; D·伯德索尔; J·J·沙伊贝尔; D·S·康纳尔
在胺或胺/溶剂中,将胺,例如甲胺与物料,例如还原性糖反应来制备N-烷基多羟基胺。相应地,葡萄糖与甲胺反应,得到的加合物氢化得到N-甲基葡糖胺。N-烷基多羟基胺可接着与脂肪族酯反应,产生可用作洗涤剂表面活性剂的多羟基脂肪酸酰胺。因此,洗涤剂表面活性剂可由非石油化学产物母体,例如,糖和糖原料,诸如,玉米糖浆,和由各种脂肪和油得到的脂肪酸酯得到。
11 8-(2-HYDROXYPHENOXY)OCTYLDIETHANOLAMINE AND SALTS THEREOF FOR DELIVERY OF ACTIVE AGENTS PCT/US2005013174 2005-04-18 WO2005115406A3 2006-08-03 GSCHNEIDNER DAVID
The present invention provides 8-(2-hydroxyphenoxy)octyldiethanolamine) and salts thereof, compositions containing the same and one or more active agents, and methods of administering active agents with the same. The delivery agents of the present invention are well suited for forming non-covalent mixtures with active agents for oral, intracolonic, pulmonary, and other routes of administration to animals.
12 2,4-pentadiene acid derivative with retinoid-like biological activity JP50137697 1996-06-04 JP4052668B2 2008-02-27 チャンドララトナ,ロシャンタ・エイ; ブリゴンダ,ビディアサガー
13 Reduction method of amino acids and their derivatives JP50915396 1995-08-17 JP3850438B2 2006-11-29 ドラウツ カールハインツ; ヒルペルト ハンス; コッテンハーン マッティアス
14 High purity alkanolamine and its producing method JP2001020869 2001-01-30 JP2002220364A 2002-08-09 MURAOKA KENJI; SAITO TOSHIAKI; SUMINO YUKIO
PROBLEM TO BE SOLVED: To provide high purity alkanolamine containing iron of 50 ppb or less and a method for producing high purity alkanolamine especially containing trace amount of metal. SOLUTION: The inner wall of equipment from a distillation column overhead through a storage tank contacting with alkanolamine is at least partially coated with resin or the like in the separation and purification step to produce high purity alkanolamine. COPYRIGHT: (C)2002,JPO
15 Production of optically active compound JP11895797 1997-05-09 JPH10304893A 1998-11-17 IMURA AKIHIRO; ITOU MIKIHIRO
PROBLEM TO BE SOLVED: To efficiently obtain the subject compound having a high optical purity useful as an intermediate for producing various medicines, by treating a γ-substituted amino-β-hydroxybutyric acid derivative in the presence of a culture solution of a bacterium, a cell (treated substance), etc. SOLUTION: A γ-substituted amino-β-hydroxybutyric acid derivative of the formula (R 1 is an amino-protecting group; R 2 is H, a 1-6C alkyl, a 2-7C alkoxyalkyl) (e.g. 4-benzyloxycarbonylamino-3-hydroxybutanoic acid) is treated in the presence of a culture solution of a bacterium of the genus Brevibacterium such as IFO12, 170, the cell of the bacterium or the treated substance of the bacterium and is converted into one configuration of steric configurations of a hydroxyl group at the β-position to give the objective highly optically active β-substituted amino-β-hydroxybutyric acid derivative useful as an intermediate for producing various medicines. COPYRIGHT: (C)1998,JPO
16 Tertiary amino alcohol and a method of manufacturing the same JP21904689 1989-08-25 JP2756000B2 1998-05-25 SOTODANI KOSHIRO; ABE YUTAKA; AIKAWA JUN; TANIGUCHI HIDEKI; NISHIMOTO UICHIRO
17 Chirality-identifying agent and separator for chromatography JP30909291 1991-11-25 JPH05139999A 1993-06-08 OI TAKAFUMI; KITAHARA HAJIME; NAKAMURA REIKO; SEIKO FUMIKO
PURPOSE: To provide a chirality-identifying agent comprising a tartaric acid monoamide compound and used for resolving the enantiomer mixture of a chirality-having compound such as an amino acid or a hydroxy acid in a liquid chromatography. CONSTITUTION: A chirality-identifying agent comprises a compound of the formula [R 1, R 2 are alkyl (which may contain an unsaturated bond and an aromatic group or hydroxy group as a substituent), aryl, but R 1, R 2 are different from each other; R 3 is H, alkyl, etc.; the total amount of the carbon atoms in R 1, R 2 and R 3 is ≥8, and the tartaric acid part is optically active]. For example, (R,R)-tartaric acid-mono-1-(R)-(α-naphthyl) ethylamide. The compound of the formula is obtained by reacting a hydroxyl-protected tartaric acid, etc., with a compound of formula CH(R 1)(R 2)NH(R 3) and subsequently removing the protecting group from the reaction product. COPYRIGHT: (C)1993,JPO&Japio
18 Novel beta-hydroxy-beta,beta-bis(trifluoromethyl)amine derivative and production thereof JP25148189 1989-09-27 JPH03112947A 1991-05-14 KOBAYASHI YOSHIRO; TAGUCHI TAKEO; SUDA YOSHIMITSU; HAMOCHI MASAHIKO
NEW MATERIAL:The compound of formula I (R 1 and R 2 are H, alkyl, aryl or aralkyl which may contain unsaturated bond, ether bond, halogen and OH) or formula II (R 2 is H, alkyl, aryl or aralkyl; n is 3 or 4). EXAMPLE: 1,1,1-Trifuloro-2-trifluoromethyl-3((S)-1-phenylethyl)aminohexane-2,6- diol-6-tetrahydropyranyl ether. USE: Intermediate for pharmaceuticals, agricultural chemicals or catalyst for organic syntheses. PREPARATION: The compound of formula I can be produced by reacting a compound of formula III (R 3 is group defined by R 1) with a compound of formula R 2NH 2 in the presence of an acid acceptor and a phase transfer catalyst. The compound of formula II is produced by converting a part of R 1 of the compound of formula III to R 2NH 2 and subjecting to intramolecular reaction in the presence of an acid acceptor and a phase-transfer catalyst. COPYRIGHT: (C)1991,JPO&Japio
19 4-substituted cyclohexylamine derivative and fungicide containing same JP22056887 1987-09-04 JPS6368545A 1988-03-28 FUUBERUTO ZAUTAA; MATEIASU TSUIPURIISU; NORUBERUTO GETSU; EEBAAHARUTO AMAAMAN; ERUNSUTO HAINRIHI POMAA
20 Fluorinated nitro- and aminoalcohols JP26786586 1986-11-12 JPS62120345A 1987-06-01 ARUBAATO KEI BETSUKU; DEIITAA ZEEBATSUHA
QQ群二维码
意见反馈